Cawachi Limited
Notice Regarding the Recording of Extraordinary Loss
In the fiscal year ending March 2026, an impairment loss on fixed assets of 2,117 million yen was recorded as an extraordinary loss and reflected in the financial summary.
Key Figures
- Extraordinary Loss (Impairment Loss): 2,117 million yen
- Impairment Loss on Buildings and Structures: 1,960 million yen
- Other Fixed Assets Impairment Loss: 210 million yen
AI要約
Regarding the Recording of Extraordinary Loss
Kawachi Pharmaceutical Co., Ltd. recorded an impairment loss of 2,117 million yen as an extraordinary loss in the fiscal year ending March 2026 (March 16, 2025 to March 15, 2026) after reviewing the recoverability of fixed assets. The breakdown consists of 1,960 million yen for buildings and structures and 210 million yen for other assets.
Impact on Business Performance
This extraordinary loss has been reflected in the consolidated financial summary for the fiscal year ending March 2026, published on the same day, negatively impacting business results. However, the document does not specify the exact impact on operating income or net income.
Kawachi Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
